Effect of drug-light interval on the mode of action of Photofrin photodynamic therapy in a mouse tumor model.
Our objective was to examine the effect of time intervals between Photofrin injection and laser irradiation [i.e., drug-light interval (DLI)] on the mode of action of Photofrin photodynamic therapy (PDT). Kunming mice transplanted with sarcoma-180 cells were used as an animal model. The tumor-bearing mice in the control group were given neither photosensitizer nor laser irradiation. PDT groups were given intravenous (i.v.) injection of Photofrin (7.5 mg/kg) prior to being irradiated with a 630 nm laser at 120 J/cm(2) at different DLIs (1 min-48 h). Tumors and overlying skin were visually examined daily. Histopathological and electron microscopic examinations were carried out 48 h after PDT. Survival rates were recorded. The mice in the groups that had experienced short DLIs (<60 min) showed stronger skin reactions than the groups subjected to long DLIs (>6 h). Histological examination showed that antitumor effects were achieved mainly by the destruction of tumor blood vessels and the formation of thrombosis at short DLIs, whereas, at long DLIs, the tumor cells were killed directly by PDT-mediated cytotoxicity. Electron microscopy revealed various degrees of mitochondrial swelling. The survival rate of the mice subjected to long DLIs was slightly higher than that of the mice subjected to short DLIs. Both vascular (e.g., tumor vessel destruction) and cellular (e.g., cytotoxicity) effects contributed to Photofrin PDT-induced tumor ablation.
Li
Li-Bo
LB
Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, PR China. li_libo2008@yahoo.com.cn
Luo
Rong-Cheng
RC
D000818:Animals; D017323:Dihematoporphyrin Ether / Q000008:administration & dosage / Q000627:therapeutic use*; D054023:Lasers, Semiconductor; D028022:Low-Level Light Therapy; D008297:Male; D051379:Mice; D046529:Microscopy, Electron, Transmission; D009368:Neoplasm Transplantation; D010778:Photochemotherapy / Q000009:adverse effects / Q000379:methods*; D017319:Photosensitizing Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D012510:Sarcoma 180 / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D012867:Skin / Q000473:pathology / Q000528:radiation effects; D013997:Time Factors
D017319:Photosensitizing Agents; D017323:Dihematoporphyrin Ether